US Patent

US11746141 — Modified collagen

Formulation · Assigned to INNOCOLL PHARMACEUTICALS Ltd · Expires 2033-01-09 · 7y remaining

Vulnerability score 50/100 Moderate — design-around opportunities exist

What this patent protects

This patent protects a method of preparing modified collagen through a process of freezing, dehydrating, and maturing.

USPTO Abstract

The present invention relates to a modified collagen obtainable by providing isolated collagen; freezing the isolated collagen; dehydrating the frozen collagen; and maturing the dehydrated collagen. Also disclosed are methods of preparing the modified collagen and uses thereof.

Drugs covered by this patent

Bupivacaine Hydrochloride And Epinephrine (Bupivacaine Hydrochloride) · Pfizer

Patent Metadata

Patent number: US11746141
Jurisdiction: US
Classification: Formulation
Expires: 2033-01-09
Drug substance claim: No
Drug product claim: Yes
Assignee: INNOCOLL PHARMACEUTICALS Ltd
Source: FDA Orange Book + USPTO grounding via Google Patents

Bibliographic data sourced from FDA Orange Book + USPTO public records. Plain-English summary generated by AI grounded in source text. Patent term extensions (PTR, SPC, pediatric) may shift the effective expiry. Not legal advice.

Track this patent

Get a daily-checked alert when vulnerability score, expiry, classification, or assignee changes. Email, Slack, or Teams delivery. Pro: 50 watches, Free: 3.